nivolumab,ipilimumab,cabozantinib,sunitinib
bms,pfizer
['lba443', 'gu ', '#603', 'urothelial', 'urothelial carcinoma', 'renal,(-adrenal)', 'check,mate,274', 'cm274', 'scienceatbms', 'bms', 'bristol']
#ascogu23 reminder: join us on 2/17 at 2:42pm pst, for oral presentation by dr. , on 36-month median follow-up data from our checkmate-274 trial comparing #adjuvant #immunotherapy vs placebo in high-risk #miuc patients-lba#443 
Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below: